NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026

SANTA ANA, Calif., March 10, 2026 — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced upcoming oral and poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (“AD/PD™ 2026”), taking place March 17-21, 2026, in Copenhagen, Denmark and virtually.

The presentations will highlight a new integrated analysis of patient-level data from two previously completed Phase 1 studies evaluating troculeucel in patients with Alzheimer’s disease. In these analyses, participants across both trials were evaluated as a combined cohort to assess dose-response relationships on cognitive measures. Biomarker associations, including plasma glial fibrillary acidic protein (“GFAP”) as an indicator of astrocytic injury and activation that may reflect disease state in Alzheimer’s disease, were also examined.

AD/PD™ 2026 is the leading international conference on Alzheimer’s and Parkinson’s disease research, bringing together thousands of top scientists, clinicians, and industry experts from around the world providing a dynamic platform to share the latest discoveries, clinical trial results, and innovative therapeutic strategies.

Oral Presentation Details:

Title:

First-in-Class NK Cell Therapy Troculeucel Shows Cognitive Benefit in Moderate Alzheimer’s: Dose Dependent Phase 1 Findings (ID 1021)

Session Name:

Translational Treatment Strategies in AD & FTD; New Targets

Session Type:

Symposium

Presentation Date:

Saturday, March 21, 2026, at 2:10 –2:25 PM CET, Denmark (8:10–8:25 AM ET)

Location:

Auditorium 11

Poster Session Details:

Title:

Plasma GFAP as a Biomarker for Anti-inflammatory Response and Cognitive Improvement in Phase 1 Trials of Troculeucel for Alzheimer’s Disease (ID 1060)

Session Topic:

Theme A: β-Amyloid Diseases / A04.h. Imaging, Biomarkers, Diagnostics: CSF- and blood- based biomarkers

Session Type:

Poster – Shift 2

Session Dates:

Friday, March 20, 2026 – Saturday, March 21, 2026, 10:00 AM–5:00 PM CET, Denmark (4:00 –11:00 AM ET)

Location:

Exhibition Hall, Poster Section

The data to be presented reflect new analyses of Phase 1 clinical studies and do not include results from the Company’s ongoing Phase 2 trial of troculeucel in Alzheimer’s disease.

Previously disclosed data for troculeucel in Alzheimer’s disease and solid tumors can be found on the Scientific Publications page of the Company’s website at https://nkgenbiotech.com/scientific-publications/. News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company’s website at https://nkgenbiotech.com/news/.

About Troculeucel

Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market.

About NKGen Biotech

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.

Internal Contact

Denise Chua, MBA, CLS, MLS (ASCP) SVP, Corporate Affairs 949-396-6830 [email protected]

External Contacts:

Kevin Gardner Managing Director LifeSci Advisors, LLC [email protected]